Financial incentives provided to hospitals in Japan led to a significant increase in biosimilar oncology drug prescriptions.

Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers ...

Now, two other cases, focused on the pricing of two cancer medicines - lenalidomide and trastuzumab - are quietly making their way through the Competition Commission's processes. These cases could ...

The National Institute for Health and Care Excellence (Nice) said it is "extremely disappointed" it will be unable to ...

Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name ...

Barbara O’Brien, MD, discusses the background behind the phase 2 TBCRC049 study investigating the combination of tucatinib, trastuzumab, and capecitabine for the treatment of patients with ...

ADCs such as datopotamab deruxtecan (Dato-DXd), trastuzumab deruxtecan (Enhertu), and sacituzumab govitecan (Trodelvy) have ...

I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...